非体外循环与体外循环对糖尿病患者5年冠脉搭桥临床结局的影响
该多中心随机对照试验比较了需药物治疗的糖尿病患者接受非体外循环(off-pump)与体外循环(on-pump)CABG的5年临床结局。共纳入835例患者(off-pump组402例,on-pump组433例),5年全因死亡率off-pump组为20.2%,on-pump组为14.1%(p=0.0198),MACE及其他终点无显著差异。结论提示on-pump可能改善5年生存,但需未来试验验证。
要点
- 糖尿病患者on-pump CABG的5年全因死亡率显著低于off-pump(14.1% vs 20.2%,p=0.0198)。
- MACE、再次血运重建和非致命性心肌梗死两组间无显著差异。
- 心源性死亡off-pump有更差趋势(9.0% vs 6.25%,p=0.137),但未达显著。
核心结论
- 对于接受药物治疗的糖尿病患者,on-pump CABG在5年生存方面显示出优于off-pump的强烈趋势,绝对差异为6.1%。
- 未发现off-pump在任何5年终点上有优势。
研究设计与样本
- 美国多中心随机对照试验(Department of Veterans Affairs Randomization On versus Off Bypass Follow-up Study)。
- 2002年至2008年纳入835例接受药物治疗(口服降糖药或胰岛素)的糖尿病患者,off-pump组402例,on-pump组433例。
主要发现
- 5年全因死亡率:off-pump组20.2%,on-pump组14.1%(p=0.0198)。
- 5年MACE:off-pump组32.6%,on-pump组28.6%(p=0.216)。
- 5年再次血运重建:off-pump组12.4%,on-pump组11.8%(p=0.770)。
- 5年非致命性心肌梗死:off-pump组12.7%,on-pump组10.4%(p=0.299)。
- 5年心源性死亡:off-pump组9.0%,on-pump组6.25%(p=0.137)。
关键数值与推荐
- 主要终点为5年全因死亡和MACE(全因死亡、心肌梗死或再次血运重建的复合终点)。
- 次要终点包括心源性死亡及MACE组分。
- 统计采用p≤0.01为显著,p>0.01且≤0.15为非显著趋势。
临床怎么用
- 对于需药物治疗的糖尿病患者,选择on-pump CABG可能有利于改善5年生存。
- off-pump CABG在该人群中未显示任何5年终点优势,决策时应综合考虑。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: For diabetic patients who require coronary artery bypass graft (CABG) operation, controversy persists whether an off-pump or an on-pump approach may be advantageous. This US-based, multicenter, randomized, controlled trial, Department of Veterans Affairs Randomization On versus Off Bypass Follow-up Study, compared diabetic patients' 5-year clinical outcomes for off-pump versus on-pump procedures. METHODS: From 2002 to 2008, 835 medically treated (ie, oral hypoglycemic agent or insulin) diabetic patients underwent either off-pump (n = 402) or on-pump (n = 433) CABG. Five-year primary end points included all-cause death and major adverse cardiovascular events (MACE; composite included all-cause death, myocardial infarction, or repeat revascularization). Secondary 5-year end points included cardiac death and MACE-related components. With baseline risk factors balanced, outcomes were evaluated by using a p value less than or equal to 0.01; nonsignificant trends were reported for p values greater than 0.01 and less than or equal to 0.15. RESULTS: Five-year all-cause death rates were 20.2% off pump versus 14.1% on pump (p = 0.0198). No differences were seen in MACE (32.6% off-pump approach versus 28.6% on-pump approach, p = 0.216), repeat revascularization (12.4% off-pump approach versus 11.8% on-pump approach, p = 0.770), and nonfatal myocardial infarction (12.7% off-pump approach versus 10.4% on-pump approach, p = 0.299). Cardiac death trended worse with off-pump CABG (9.0%) than with on-pump CABG (6.25%, p = 0.137). Sensitivity analyses that removed conversions confirmed these findings. CONCLUSIONS: With a 6.1% absolute difference, a strong trend toward improved 5-year survival was observed with on-pump CABG for medically treated diabetic patients. No off-pump advantage was found for any 5-year end points. A future clinical trial now appears warranted to rigorously compare off-pump versus on-pump longer term outcomes for diabetic patients.
引用
- Shroyer ALW, Quin JA, Wagner TH, et al. Off-Pump Versus On-Pump Impact: Diabetic Patient 5-Year Coronary Artery Bypass Clinical Outcomes. Ann Thorac Surg. 2018. PMID: 30273568. doi:10.1016/j.athoracsur.2018.07.076
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。